Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Homocysteine lowering in end-stage renal disease: is there any cardiovascular benefit?

Homocysteine lowering in end-stage renal disease: is there any cardiovascular benefit? Circulation. 2010 Mar 30; 121(12):1379-81.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.